All In Biotech

NDA 205625 · Glaxosmithkline

Arnuity Ellipta

Fluticasone Furoate · Inhalation

Last checked: Nov 20, 2026Latest source record: Oct 18, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Aug 20, 2014

Approved uses

3

Original approval plus efficacy supplements

Registered trials

737

240 Phase 3, 19 recruiting

FAERS reports

9,896

6,929 serious, 616 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 6, 2025.

Fluticasone Furoate ELLIPTA is indicated for the maintenance treatment of asthma in adult and pediatric patients aged 5 years and older. Limitations of Use Fluticasone Furoate ELLIPTA is NOT indicated for the relief of acute bronchospasm. Fluticasone Furoate ELLIPTA is an inhaled corticosteroid indicated for the maintenance treatment of asthma in adult and pediatric patients aged 5 years and older. ( 1 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1 , 5.2 )

Mechanism: Fluticasone furoate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is approximately 29.9 times that of dexamethasone and 1.7 times that of fluticasone propionate. The clinical relevance of these findings is unknown. The precise mechanism through which fluticasone furoate affects asthma symptoms is not known. Inflammation is an important component in the pathogenesis of asthma. Corticosteroids have been shown to have a wide range of actions on...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.2MG/INH · POWDER, INHALATION · Prescription
  • ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.05MG/INH · POWDER, INHALATION · Prescription
  • ARNUITY ELLIPTA · FLUTICASONE FUROATE 0.1MG/INH · POWDER, INHALATION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Furoate" as an intervention, any sponsor and status, largest first.

All 737 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea1,572
  • drug ineffective1,570
  • asthma1,315
  • off label use926
  • cough911
  • wheezing908
  • therapeutic product effect incomplete766
  • nausea686
  • pain665
  • pneumonia661
  • macular degeneration632
  • malaise620

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20071
20084
20093
201017
201152
2012266
201343
201476
2015156
2016219
2017423
2018583
2019690
2020852
20211,246
20221,096
20231,134
20241,145
20251,105
2026785

Recalls

1 FDA enforcement reports for this application.

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Arnuity Ellipta (Fluticasone Furoate)

2024 spending

$200M

Beneficiaries

181,821

659,581 claims

Per beneficiary

$1,099

$7.37 per unit

View as table
YearSpending
2020$80,943,847
2021$85,013,031
2022$88,815,140
2023$98,260,735
2024$199,856,123

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 243 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.